

Supplementary Table 1 Study populations for GWAS meta-analysis and replication genotyping

Phase	Type	Study center	Cases	Controls	Total
Discovery	Illumina HumanHap660W and/or 610	FLCCA, NCI	5457	4493	9950
	Illumina HumanOmni1 and/or OmniEx	NCC, Japan	777	1,003	1780
	Illumina HumanHap610	Univ of Tokyo, Japan	356	457	813
	Affymetrix 6.0	Nanjing, China	287	324	611
<b>Subtotal</b>			<b>6877</b>	<b>6277</b>	<b>13154</b>
Replication	TaqMan	Jinan, China <sup>a</sup>	1,215	1,205	2420
	TaqMan	Wuhan, China	364	460	824
	TaqMan	Shenyang, China <sup>b</sup>	628	645	1273
	TaqMan	Nanjing, China	504	500	1004
	TaqMan	Beijing, China	445	417	862
	TaqMan	Tianjin, China	310	309	619
	TaqMan	Shanghai, China <sup>c</sup>	762	286	1048
	TaqMan	Taiwan <sup>d</sup>	419	277	696
	TaqMan	NCCI, Japan	110	213	323
	TaqMan	NCCH, Japan	364	351	715
	Invader	BBJ NCCH, Japan	654	2,211	2865
	TaqMan	Japan NCCI JPHC <sup>e</sup>	103	172	275
	<b>Subtotal</b>			<b>5,878</b>	<b>7,046</b>
<b>Grand Total</b>			<b>12,755</b>	<b>13,323</b>	<b>26,078</b>

<sup>a</sup> Cases and controls were enrolled at Shandong Tumor Hospital; <sup>b</sup> Samples were genotyped at Tianjing; <sup>c</sup> Part of the samples were collected and genotyped by Shanghai Pulmonary Hospital, and part of the samples were collected by Fudan University and genotyped at Tianjin; <sup>d</sup> Part of the samples was genotyped in CGR, NCI; <sup>e</sup> Samples were genotyped in CGR, NCI